Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

British Journal of Cancer
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. british journal of cancer
  3. regular article
  4. article
Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis
Download PDF
Download PDF
  • Regular Article
  • Open access
  • Published: 16 October 2001

Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis

  • Ö U Ataman1,3,
  • S M Bentzen1,
  • M I Saunders2 &
  • …
  • S Dische2 

British Journal of Cancer volume 85, pages 1113–1118 (2001)Cite this article

  • 568 Accesses

  • 12 Citations

  • Metrics details

This article has been updated

Abstract

The aim of this study was to identify possible failure-specific prognostic factors in non-small-cell lung cancer. Clinical outcome was analysed in 549 patients participating in the randomized controlled trial of CHART vs conventional radiotherapy. Local failure and distant failure with or without concurrent local relapse were subjected to a competing risk analysis using an accelerated failure-time model with a log-logistic hazard function. Randomization to CHART (2P = 0.005), increasing age (2P = 0.036) and female sex (2P = 0.09) was all associated with a prolonged interval to failure. Advanced clinical stage was associated with a decreased interval to failure (2P = 0.004) and a significantly increased risk (2P = 0.009) of failing in distant rather than in local position. From this model, prognostic indices for local and distant failure were estimated for each individual patient. Competing risk analysis allows identification of patients with different failure patterns, and may provide a means of stratifying patients for intensified local or systemic therapy. © 2001 Cancer Research Campaign http://www.bjcancer.com

Similar content being viewed by others

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer

Article Open access 08 December 2020

Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer

Article Open access 08 December 2020

A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer

Article Open access 15 March 2021

Article PDF

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  • Albain KS, Crowley JJ, LeBlanc M and Livingstone RB (1991) Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618–1626

    Article  CAS  Google Scholar 

  • Ardizzoni A, Grossi F, Scolaro T, Giudici S, Foppiano F, Boni L, Tixi L, Cosso M, Mereu C, Battista Ratto G, Vitale V and Rosso R (1999) Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer. Br J Cancer 81: 310–315

    Article  CAS  Google Scholar 

  • Arriagada R, Kramar A, Le Chevalier T and De Cremoux H (1992) Competing events determining relapse-free survival in limited small-cell lung carcinoma. J Clin Oncol 10: 447–451

    Article  CAS  Google Scholar 

  • Ball D, Bishop J, Smith J, O’Brien P, Davis S, Ryan G, Olver I, Toner G, Walker Q and Joseph D (1999) A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 52: 129–136

    Article  CAS  Google Scholar 

  • Bentzen SM, Poulsen HS, Kaae S, Myhre Jensen O, Johansen H, Mouridsen HT, Daugaard S and Arnoldi C (1988) Prognostic factors in osteosarcomas A regression analysis. Cancer 62: 194–202

    Article  CAS  Google Scholar 

  • Bentzen SM, Thames HD, Travis EL, Kian Ang K, Van Der Scheren E, Dewit L and Dixon DO (1989) Direct estimation of latent time for radiation injury in late responding normal tissues: gut, lung, and spinal cord. Int J Radiat Oncol Biol Phys 55: 27–43

    Article  CAS  Google Scholar 

  • BMDP User's Guide (1992a), Version 7, ed. Dixon WJ. pp 825–864, Wiley

  • BMDP User's Guide (1992b), Version 7 ed. Dixon WJ. pp 825–864, Wiley

  • Chapman JW, Fish EB and Link MA (1999) Competing risk analyses for recurrence from primary breast cancer. Br J Cancer 79: 1508–1513

    Article  CAS  Google Scholar 

  • Ciampi A, Lawless JF, Mc Kinney SM and Singhal K (1988) Regression and recursive partition strategies in the analysis of medical survival data. J Clin Epidemiol 41: 737–748

    Article  CAS  Google Scholar 

  • Cox JD, Scott CB, Byhardt RW, Emami B, Russell AH, Fu KK, Parliament MB, Komaki R and Gaspar LEW (1999) Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCLC): Analysis of Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 43: 505–509

    Article  CAS  Google Scholar 

  • Kalbfleisch JD and Prentice RL (1980). The statistical Analysis of Failure Time Data, 21–38, 179–188, John Wiley: New York

    Google Scholar 

  • Komaki R, Scott CB, Byhardt R, Emami B, Asbell SO, Russell AH, Roach M, Parliament MB and Gaspar LE (1998) Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). Int. J. Radiat Oncol Biol. Phys 42: 263–267

    Article  CAS  Google Scholar 

  • Kramar A, Pejovic MH and Chassagne D (1987) A method of analysis taking into account competing events: Application to the study of digestive complications following irradiation for cervical cancer. Statist Med 6: 785–794

    Article  CAS  Google Scholar 

  • Lagakos SW (1978) A covariate model for partially censored data subject to competing causes of failure. Appl Statist 27: 235–241

    Article  Google Scholar 

  • SAS/STAT User's Guide, (1993). SAS Institute: Cary NC 997–1025

  • Saunders M, Dische S, Barrett A, Harvey A, Griffiths G and Parmar M (on behalf of CHART Steering committee) (1999) Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol 52: 137–148

    Article  CAS  Google Scholar 

  • Scott C, Sause WT, Byhardt R, Marcial V, Pajak TF, Herskovic A and Cox JD (1997) Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer. Lung Cancer 17: 59–74

    Article  Google Scholar 

  • S-Plus 4 Guide to Statistics, (1991). Data analysis products division, Math Soft: Seattle Wa 697–710

  • Sørensen JB and Østerlind K (1999) Prognostic factors: from clinical parameters to new biological markers. In Progress and perspective in the treatment of lung cancer, Van Houtte P, Klastersky J, Rocmans P (Eds). pp 1–21, Springer

    Google Scholar 

  • Stevens CW, Lee JS, Cox J and Komaki R (2000) Novel approaches to locally advanced unresectable non-small cell lung cancer. Radiother Oncol 55: 11–18

    Article  CAS  Google Scholar 

  • Takigawa N, Segawa Y, Okahara M, Maeda Y, Takata I, Kataoka M and Fujii M (1996) Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 15: 67–77

    Article  CAS  Google Scholar 

  • Werner-Wasik M, Scott C, Cox JD, Sause WT, Byhardt RW, Asbell S, Russell A, Komaki R and Lee JS (2000) Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally advanced non-small cell lung cancer (LA-NSCLC); identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48: 1475–1482

    Article  CAS  Google Scholar 

  • Wigren T (1997) Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol 44: 9–15

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gray Cancer Institute, Mount Vernon Hospital Northwood, Middlesex, UK

    Ö U Ataman & S M Bentzen

  2. Marie Curie Research Wing, Mount Vernon Hospital Northwood, Middlesex, UK

    M I Saunders & S Dische

  3. Radiation Oncology Department, Dokuz Eylül University Medical School, Izmir, Turkey

    Ö U Ataman

Authors
  1. Ö U Ataman
    View author publications

    Search author on:PubMed Google Scholar

  2. S M Bentzen
    View author publications

    Search author on:PubMed Google Scholar

  3. M I Saunders
    View author publications

    Search author on:PubMed Google Scholar

  4. S Dische
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and permissions

About this article

Cite this article

Ataman, Ö., Bentzen, S., Saunders, M. et al. Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis. Br J Cancer 85, 1113–1118 (2001). https://doi.org/10.1054/bjoc.2001.2049

Download citation

  • Received: 30 May 2001

  • Revised: 05 July 2001

  • Accepted: 13 July 2001

  • Published: 16 October 2001

  • Issue date: 19 October 2001

  • DOI: https://doi.org/10.1054/bjoc.2001.2049

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • NSCLC
  • CHART
  • competing risks
  • failure-specific prognostic factors
Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Follow us on Twitter
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information
  • Open access publishing
  • About the Editors
  • Contact
  • Special Issues
  • For Advertisers
  • Subscribe

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

British Journal of Cancer (Br J Cancer)

ISSN 1532-1827 (online)

ISSN 0007-0920 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited